Neuroone Capex To Revenue vs Ev To Sales Analysis

NMTC Stock

USD 0.76 0.02 2.70%

Neuroone Medical financial indicator trend analysis is infinitely more than just investigating Neuroone Medical Tec recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neuroone Medical Tec is a good investment. Please check the relationship between Neuroone Medical Capex To Revenue and its Ev To Sales accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Capex To Revenue vs Ev To Sales

Capex To Revenue vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neuroone Medical Tec Capex To Revenue account and Ev To Sales. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Neuroone Medical's Capex To Revenue and Ev To Sales is -0.17. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of Neuroone Medical Technologies, assuming nothing else is changed. The correlation between historical values of Neuroone Medical's Capex To Revenue and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Neuroone Medical Technologies are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Capex To Revenue i.e., Neuroone Medical's Capex To Revenue and Ev To Sales go up and down completely randomly.

Correlation Coefficient

-0.17

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from Neuroone Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neuroone Medical Tec current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

At present, Neuroone Medical's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 14.55, whereas Enterprise Value Over EBITDA is forecasted to decline to (9.44).

Neuroone Medical fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Total Liab	Total Current Assets	Common Stock	Other Stockholder Equity	Short Term Debt	Current Deferred Revenue	Accounts Payable	Other Liab	Net Tangible Assets	Intangible Assets	Net Invested Capital	Net Working Capital	Capital Stock	Property Plant And Equipment Net
Common Stock Shares Outstanding		0.61	-0.13	0.64	0.37	0.48	-0.46	-0.96	0.47	0.47	0.86	0.67	0.65	0.6	0.9	0.95	-0.25	-0.11	0.61	0.39	0.93	-0.48	0.56	0.7	0.73	0.87
Total Assets	0.61		-0.07	0.41	0.55	0.91	-0.94	-0.75	0.96	0.97	0.78	0.04	0.41	1.0	0.56	0.78	-0.15	0.29	0.66	0.48	0.75	-0.26	0.98	0.98	0.67	0.85
Short Long Term Debt Total	-0.13	-0.07		0.61	0.74	-0.41	0.24	0.01	-0.04	-0.06	0.13	0.39	0.61	-0.09	0.14	-0.05	0.98	0.55	0.33	0.43	-0.29	0.7	-0.04	-0.03	0.0	-0.06
Other Current Liab	0.64	0.41	0.61		0.83	0.05	-0.15	-0.69	0.31	0.29	0.67	0.77	0.94	0.38	0.69	0.65	0.54	0.39	0.6	0.66	0.45	0.18	0.37	0.48	0.51	0.59
Total Current Liabilities	0.37	0.55	0.74	0.83		0.17	-0.3	-0.51	0.48	0.5	0.58	0.47	0.86	0.54	0.5	0.48	0.7	0.7	0.67	0.66	0.27	0.34	0.51	0.54	0.36	0.49
Total Stockholder Equity	0.48	0.91	-0.41	0.05	0.17		-0.98	-0.58	0.92	0.92	0.61	-0.25	0.03	0.91	0.37	0.64	-0.47	0.04	0.43	0.23	0.71	-0.41	0.92	0.88	0.56	0.71
Net Debt	-0.46	-0.94	0.24	-0.15	-0.3	-0.98		0.61	-0.97	-0.96	-0.67	0.19	-0.13	-0.95	-0.4	-0.66	0.32	-0.12	-0.53	-0.35	-0.68	0.29	-0.97	-0.93	-0.63	-0.74
Retained Earnings	-0.96	-0.75	0.01	-0.69	-0.51	-0.58	0.61		-0.64	-0.61	-0.96	-0.59	-0.68	-0.73	-0.94	-1.0	0.13	0.05	-0.76	-0.52	-0.93	0.37	-0.72	-0.83	-0.84	-0.96
Cash	0.47	0.96	-0.04	0.31	0.48	0.92	-0.97	-0.64		0.98	0.73	-0.1	0.3	0.96	0.45	0.68	-0.12	0.26	0.56	0.44	0.66	-0.16	0.99	0.95	0.66	0.77
Cash And Short Term Investments	0.47	0.97	-0.06	0.29	0.5	0.92	-0.96	-0.61	0.98		0.69	-0.1	0.31	0.97	0.42	0.66	-0.13	0.36	0.56	0.41	0.65	-0.16	0.98	0.94	0.57	0.72
Common Stock Total Equity	0.86	0.78	0.13	0.67	0.58	0.61	-0.67	-0.96	0.73	0.69		0.54	0.69	0.77	0.92	0.96	-0.01	-0.01	0.82	0.57	0.86	-0.24	0.78	0.88	0.88	0.94
Non Current Liabilities Total	0.67	0.04	0.39	0.77	0.47	-0.25	0.19	-0.59	-0.1	-0.1	0.54		0.82	0.02	0.69	0.54	0.29	0.03	0.5	0.45	0.4	0.04	-0.02	0.16	0.42	0.38
Total Liab	0.65	0.41	0.61	0.94	0.86	0.03	-0.13	-0.68	0.3	0.31	0.69	0.82		0.39	0.72	0.64	0.53	0.46	0.61	0.63	0.46	0.18	0.35	0.47	0.47	0.57
Total Current Assets	0.6	1.0	-0.09	0.38	0.54	0.91	-0.95	-0.73	0.96	0.97	0.77	0.02	0.39		0.54	0.77	-0.16	0.3	0.64	0.46	0.75	-0.27	0.98	0.97	0.65	0.83
Common Stock	0.9	0.56	0.14	0.69	0.5	0.37	-0.4	-0.94	0.45	0.42	0.92	0.69	0.72	0.54		0.92	0.0	-0.12	0.76	0.42	0.84	-0.32	0.55	0.68	0.75	0.87
Other Stockholder Equity	0.95	0.78	-0.05	0.65	0.48	0.64	-0.66	-1.0	0.68	0.66	0.96	0.54	0.64	0.77	0.92		-0.18	-0.05	0.74	0.5	0.95	-0.39	0.76	0.86	0.83	0.96
Short Term Debt	-0.25	-0.15	0.98	0.54	0.7	-0.47	0.32	0.13	-0.12	-0.13	-0.01	0.29	0.53	-0.16	0.0	-0.18		0.6	0.2	0.36	-0.41	0.73	-0.12	-0.14	-0.12	-0.17
Current Deferred Revenue	-0.11	0.29	0.55	0.39	0.7	0.04	-0.12	0.05	0.26	0.36	-0.01	0.03	0.46	0.3	-0.12	-0.05	0.6		0.12	0.23	-0.13	0.43	0.24	0.19	-0.22	-0.05
Accounts Payable	0.61	0.66	0.33	0.6	0.67	0.43	-0.53	-0.76	0.56	0.56	0.82	0.5	0.61	0.64	0.76	0.74	0.2	0.12		0.6	0.6	-0.04	0.65	0.73	0.64	0.69
Other Liab	0.39	0.48	0.43	0.66	0.66	0.23	-0.35	-0.52	0.44	0.41	0.57	0.45	0.63	0.46	0.42	0.5	0.36	0.23	0.6		0.22	0.42	0.45	0.5	0.48	0.5
Net Tangible Assets	0.93	0.75	-0.29	0.45	0.27	0.71	-0.68	-0.93	0.66	0.65	0.86	0.4	0.46	0.75	0.84	0.95	-0.41	-0.13	0.6	0.22		-0.61	0.73	0.83	0.77	0.91
Intangible Assets	-0.48	-0.26	0.7	0.18	0.34	-0.41	0.29	0.37	-0.16	-0.16	-0.24	0.04	0.18	-0.27	-0.32	-0.39	0.73	0.43	-0.04	0.42	-0.61		-0.22	-0.27	-0.28	-0.4
Net Invested Capital	0.56	0.98	-0.04	0.37	0.51	0.92	-0.97	-0.72	0.99	0.98	0.78	-0.02	0.35	0.98	0.55	0.76	-0.12	0.24	0.65	0.45	0.73	-0.22		0.98	0.69	0.83
Net Working Capital	0.7	0.98	-0.03	0.48	0.54	0.88	-0.93	-0.83	0.95	0.94	0.88	0.16	0.47	0.97	0.68	0.86	-0.14	0.19	0.73	0.5	0.83	-0.27	0.98		0.77	0.9
Capital Stock	0.73	0.67	0.0	0.51	0.36	0.56	-0.63	-0.84	0.66	0.57	0.88	0.42	0.47	0.65	0.75	0.83	-0.12	-0.22	0.64	0.48	0.77	-0.28	0.69	0.77		0.87
Property Plant And Equipment Net	0.87	0.85	-0.06	0.59	0.49	0.71	-0.74	-0.96	0.77	0.72	0.94	0.38	0.57	0.83	0.87	0.96	-0.17	-0.05	0.69	0.5	0.91	-0.4	0.83	0.9	0.87

Click cells to compare fundamentals

Neuroone Medical Account Relationship Matchups

Neuroone Medical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	5.4M	10.7M	16.0M	18.1M	26.8M	28.1M
Total Assets	4.8M	7.9M	12.8M	8.1M	5.4M	3.0M
Other Current Liab	454.9K	531.5K	632.5K	978.4K	1.1M	1.2M
Total Current Liabilities	2.4M	1.2M	3.1M	1.8M	2.2M	1.3M
Total Stockholder Equity	2.1M	6.6M	9.6M	6.2M	822.0K	1.5M
Net Debt	(2.7M)	(6.6M)	(8.0M)	(5.1M)	(1.2M)	(1.3M)
Retained Earnings	(30.9M)	(40.8M)	(50.8M)	(62.7M)	(75.0M)	(71.3M)
Cash	4.0M	6.9M	8.2M	5.3M	1.5M	2.0M
Cash And Short Term Investments	4.0M	6.9M	11.1M	5.3M	1.5M	2.3M
Liabilities And Stockholders Equity	4.8M	7.9M	12.8M	8.1M	5.4M	3.0M
Non Current Liabilities Total	337.7K	202.9K	119.6K	55.3K	2.3M	2.5M
Total Liab	2.7M	1.4M	3.2M	1.8M	4.5M	4.8M
Total Current Assets	4.2M	7.3M	12.2M	7.3M	4.6M	2.7M
Common Stock	22.2K	12.0K	16.2K	23.9K	30.8K	32.4K
Other Stockholder Equity	32.9M	47.4M	60.4M	68.9M	75.8M	79.6M
Accounts Payable	762.5K	528.8K	927.7K	685.1K	1.0M	535.1K
Net Tangible Assets	(1.4M)	1.9M	6.4M	9.5M	10.9M	11.5M
Non Current Assets Total	604.8K	646.5K	646.8K	784.4K	739.0K	445.5K
Non Currrent Assets Other	200.1K	230.9K	156.5K	(784.4K)	(706.0K)	(670.7K)
Other Current Assets	118.6K	244.0K	296.6K	263.7K	359.1K	377.0K
Intangible Assets	156.5K	134.2K	111.9K	89.6K	67.3K	113.3K
Property Plant Equipment	52.0K	448.2K	512.3K	535.0K	615.2K	646.0K
Net Invested Capital	3.1M	6.6M	9.6M	6.2M	822.0K	780.9K
Net Working Capital	1.8M	6.1M	9.1M	5.5M	2.4M	2.2M
Capital Stock	22.2K	35.8K	16.2K	23.9K	30.8K	23.9K
Property Plant And Equipment Net	448.2K	512.3K	535.0K	694.8K	671.8K	534.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Neuroone Medical Tec offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neuroone Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neuroone Medical Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neuroone Medical Technologies Stock:

How To Invest In Neuroone

Details

Is Neuroone Stock a good investment?

Details

What is Neuroone Medical's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuroone Medical. If investors know Neuroone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuroone Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.46)

Revenue Per Share

0.158

Quarterly Revenue Growth

0.311

Return On Assets

(1.43)

Return On Equity

(3.49)

The market value of Neuroone Medical Tec is measured differently than its book value, which is the value of Neuroone that is recorded on the company's balance sheet. Investors also form their own opinion of Neuroone Medical's value that differs from its market value or its book value, called intrinsic value, which is Neuroone Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuroone Medical's market value can be influenced by many factors that don't directly affect Neuroone Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neuroone Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuroone Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuroone Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neuroone Capex To Revenue vs Ev To Sales Analysis

Capex To Revenue vs Ev To Sales

Capex To Revenue vs Ev To Sales Correlation Analysis

Correlation Coefficient

Capex To Revenue

Ev To Sales

Neuroone Medical fundamental ratios Correlations

Neuroone Medical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neuroone Medical fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 0.99	Cash
Net Invested Capital	+ 0.98	Total Assets
Net Working Capital	+ 0.98	Total Assets
Short Term Debt	+ 0.98	Short Long Term Debt Total
Cash And Short Term Investments	+ 0.98	Cash

Other Stockholder Equity	- 1.0	Retained Earnings
Net Debt	- 0.98	Total Stockholder Equity
Net Invested Capital	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Property Plant And Equipment Net	- 0.96	Retained Earnings
Common Stock Total Equity	- 0.96	Retained Earnings